Dll4/Notch1 signaling from tip/stalk endothelial cell specification to stroma-dependent lung tumor inhibition: A flavor of Dll4/Notch1 pleiotropy in tumor cell biology

Translational Lung Cancer Research

Volumn 2, Issue 6, 2013, Pages 466-469

  Brizzi, Maria Felice ^a   Defilippi, Paola ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Delta like 4 (Dll4); Non small cell lung cancer (NSCLC); Notch; Tumor angiogenesis

Indexed keywords

DELTA LIKE 4 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NOTCH1 RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN JAGGED 1; UNCLASSIFIED DRUG;

ANGIOGENESIS; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CELL SPECIFICITY; CELL SURVIVAL; DNA IMMUNIZATION; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HAPLOINSUFFICIENCY; INTRACELLULAR SIGNALING; LUNG TUMOR; MOLECULARLY TARGETED THERAPY; PERICYTE; PLEIOTROPY; PROSTATE ADENOCARCINOMA; PROTEIN CLEAVAGE; STROMA; TRANSCRIPTION INITIATION; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

EID: 84959882245     PISSN: 22186751     EISSN: 22264477     Source Type: Journal    
DOI: 10.3978/j.issn.2218-6751.2013.10.18     Document Type: Article

References (26)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Custodio A, Méndez M, Provencio M. Targeted therapies for advanced non-small-cell lung cancer: current status and future implications. Cancer Treat Rev 2012;38:36-53.
3. NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008;26:4617-25.
4. Pallis AG, Syrigos KN. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC. Lung Cancer 2013;80:120-30.
5. Farnsworth RH, Lackmann M, Achen MG, et al. Vascular remodeling in cancer. Oncogene 2013. [Epub ahead of print].
6. Grépin R, Pagès G. Molecular mechanisms of resistance to tumour anti-angiogenic strategies. J Oncol 2010;2010:835680.
7. Pallis AG, Syrigos KN. Targeting tumor neovasculature in non-small-cell lung cancer. Crit Rev Oncol Hematol 2013;86:130-42.
8. Aster JC, Blacklow SC. Targeting the Notch pathway: twists and turns on the road to rational therapeutics. J Clin Oncol 2012;30:2418-20.
9. Beets K, Huylebroeck D, Moya IM, et al. Robustness in angiogenesis: notch and BMP shaping waves. Trends Genet 2013;29:140-9.
10. Blanco R, Gerhardt H. VEGF and Notch in Tip and Stalk Cell Selection. Perspect Med 2012. doi: 10.1101/cshperspect.a006569.
11. Gale NW, Dominguez MG, Noguera I, et al. Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. Proc Natl Acad Sci U S A 2004;101:15949-54.
12. del Toro R, Prahst C, Mathivet T, et al. Identification and functional analysis of endothelial tip cell-enriched genes. Blood 2010;116:4025-33.
13. Hellström M, Phng LK, Hofmann JJ, et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 2007;445:776-80.
14. Phng LK, Gerhardt H. Angiogenesis: a team effort coordinated by notch. Dev Cell 2009;16:196-208.
15. Bridges E, Oon CE, Harris A. Notch regulation of tumor angiogenesis. Future Oncol 2011;7:569-88.
16. Kuhnert F, Kirshner JR, Thurston G. Dll4-Notch signaling as a therapeutic target in tumor angiogenesis. Vasc Cell 2011;3:20.
17. Noguera-Troise I, Daly C, Papadopoulos NJ, et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 2006;444:1032-7.
18. Haller BK, Bråve A, Wallgard E, et al. Therapeutic efficacy of a DNA vaccine targeting the endothelial tip cell antigen delta-like ligand 4 in mammary carcinoma. Oncogene 2010;29:4276-86.
19. Yan M, Callahan CA, Beyer JC, et al. Chronic DLL4 blockade induces vascular neoplasms. Nature 2010;463:E6-7.
20. Dufraine J, Funahashi Y, Kitajewski J. Notch signaling regulates tumor angiogenesis by diverse mechanisms. Oncogene 2008;27:5132-7.
21. Takebe N, Nguyen D, Yang SX. Targeting Notch signaling pathway in cancer: Clinical development advances challenges. Pharmacol Ther 2013. [Epub ahead of print].
22. Collins BJ, Kleeberger W, Ball DW. Notch in lung development and lung cancer. Semin Cancer Biol 2004;14:357-64.
23. Chen Y, De Marco MA, Graziani I, et al. Oxygen concentration determines the biological effects of NOTCH-1 signaling in adenocarcinoma of the lung. Cancer Res 2007;67:7954-9.
24. Konishi J, Kawaguchi KS, Vo H, et al. Gammasecretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Res 2007;67:8051-7.
25. Ding XY, Ding J, Wu K, et al. Cross-talk between endothelial cells and tumor via delta-like ligand 4/Notch/PTEN signaling inhibits lung cancer growth. Oncogene 2012;31:2899-906.
26. Whelan JT, Kellogg A, Shewchuk BM, et al. Notch-1 signaling is lost in prostate adenocarcinoma and promotes PTEN gene expression. J Cell Biochem 2009;107:992-1001.